Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year

This article was originally published in The Gray Sheet

Executive Summary

FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development

You may also be interested in...



FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues

Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits

FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues

Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits

FDA Science Board Previews Device “Critical Path” R&D Opportunity List

Peripheral vasculature imaging is poised to be an early beneficiary of FDA's "critical path" initiative, CDRH Office of Science & Engineering Director Larry Kessler told the agency's Science Board April 22

Latest News
See All
UsernamePublicRestriction

Register

MT020426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel